Dear Colleagues,

Endometrial cancer (EC) is the fifth most common cancer in women worldwide. Global estimates show rising incidence rates in both developed and developing countries.

The genetic and molecular landscape of EC is becoming more and more important for both prognosis and treatment choice. The utilization and choice of ART for patients interested in fertility preservation depends on the type and stage of cancer, the treatment plan, the time available until the cancer treatment has to start, and whether the patient has a committed a partner. For patients who have a committed male partner, embryo cryopreservation has a long track record of being a very successful procedure for fertility preservation.

Fertility sparing approach for grade 1 endometrioid adenocarcinoma limited to the endometrium is feasible and can be considered in premenopausal patients with plans to conceive in the near future.

Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion.

This focused issue aims to provide an update about the current cutting of diagnosis management, treatment and outcomes of Endometrial cancer in reproductive age: fertility, from basic science to translation approach.

Topics in the focused issue：

• Etiology and pathogenesis of endometrial cancer in fertile women
• Biomolecular and Genetic Prognostic Factors of endometrial cancer (EC).
• Fertility-sparing approach in EC.
• Oocyte vitrification and fertility preservation
• Ethical and medico-legal implication
• Oncofertility and Reproductive Counseling
• Artificial intelligence application in EC
• Stem cells as therapy for EC
• Fertility-preservation approach in in women affected by endometrial
• Sexuality in reproductive aged women affected by EC

Dr. Giuseppe Gullo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• endometrial cancer
• fertility preservation
• vitrification ,oncofertility,fertility sparing
• artificial intelligence ,stem cells
• ethical and medico-legal implication